Lyden, Patrick <br/><br/>
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.  [electronic resource] 

 -  Annals of neurology  01 2019 
 - 125-136 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1531-8249 
<br/><br/><label>Standard No.: </label>10.1002/ana.25383  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Brain Ischemia--diagnostic imaging<br/>Combined Modality Therapy--methods<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Protein C--administration & dosage<br/>Recombinant Proteins--administration & dosage<br/>Severity of Illness Index<br/>Single-Blind Method<br/>Stroke--diagnostic imaging<br/>Thrombectomy--methods<br/>Tissue Plasminogen Activator--administration & dosage